Literature DB >> 32058795

How Does Isolated Medial Patellofemoral Ligament Reconstruction Influence Patellar Height?

Francesco Luceri1,2, Julien Roger1, Pietro Simone Randelli3,4, Sébastien Lustig1,5, Elvire Servien1,6.   

Abstract

BACKGROUND: Reconstruction of the medial patellofemoral ligament (MPFL) is the gold standard treatment for recurrent patellar dislocation. Patella alta has been reported in about half of patients with recurrent patellofemoral instability. HYPOTHESIS: MPFL reconstruction (MPFLr) has a beneficial role in the correction of patellar height in patients with mild patella alta (Caton-Deschamps index [CDI] between 1.20 and 1.40). STUDY
DESIGN: Case series; Level of evidence, 4.
METHODS: Skeletally mature patients, with no history of previous or concomitant knee surgical procedures, who underwent isolated MPFLr using hamstring autograft for recurrent patellar instability between 2005 and 2018, were included in this study. The authors calculated CDI, modified Insall-Salvati index (MISI), and Blackburne-Peel index (BPI) ratios. Measurements done by 2 independent observers were calculated and used to compare pre- and postoperative patellar height (patella alta: CDI >1.20).
RESULTS: A total of 89 patients (95 knees) were included in the study, with a mean age of 25.0 years (range, 15.0-45.0 years). There were 70% women and 30% men. We found patella alta in 35.8% of cases preoperatively. Among them, 79.4% had reduced patellar height indices, within normal limits, postoperatively (mean follow-up, 18.4 ± 12.0 months). All the ratios showed a significant reduction in patellar height after surgery (CDI: 0.19 [range, -0.05, 0.60]; MISI: 0.22 [-0.14, 0.76]; BPI: 0.18 [-0.08, 0.59]; P < .00001). The CDI of 79.4% of the study knees was reduced to within normal limits postoperatively. The CDI was maintained within normal limits postoperatively in 93.4% of the knees with normal patellar height and reduced to normal in 50% of the knees with severe patella alta before surgery . No patient reported patella infera before surgery, whereas this condition was found in 8.2% of study patients postoperatively. A moderate correlation was reported between preoperative radiographic indices and their reduction after surgery (CDI: P < .001, ρ = 0.39; MISI: P < .001, ρ = 0.39; BPI: P < .001, ρ = 0.48).
CONCLUSION: The higher the preoperative patellar height, the more important is the lowering effect of MPFLr using the hamstring for patellar instability. Bony procedures should not be indicated in patients with patellar instability and a CDI between 1.20 and 1.40.

Entities:  

Keywords:  medial patellofemoral ligament; patellar height; patellar instability; reconstruction

Year:  2020        PMID: 32058795     DOI: 10.1177/0363546520902132

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  4 in total

1.  The Dynamic Effect of Anterior Cruciate Ligament Deficiency on Patellar Height.

Authors:  Francesco Luceri; Mattia Basilico; Cécile Batailler; Pietro Simone Randelli; Sébastien Lustig; Elvire Servien
Journal:  Indian J Orthop       Date:  2022-06-20       Impact factor: 1.033

2.  Clinical Outcomes and Prognostic Factors in Patients With Recurrent Patellar Lateral Dislocation Treated With Isolated Medial Patellofemoral Ligament Reconstruction: A Retrospective Single-Center Analysis.

Authors:  Zhidong Zhao; Yuxing Wang; Ji Li; Haoran Wang; Xiaowei Bai; Qi Wang; Zhongli Li
Journal:  Orthop J Sports Med       Date:  2021-04-12

3.  Effects of Lateral Patellar Retinaculum Release for Recurrent Patella Dislocation: A Prospective Study.

Authors:  Xing-Liang Wang; Chao Peng; You-Wei Tu; Yun-Peng Liu; Wei Zhang; Yan Zhang; Guo-Jun Hua
Journal:  Int J Gen Med       Date:  2021-09-10

4.  Autologous Matrix-Induced Chondrogenesis (AMIC) for Isolated Retropatellar Cartilage Lesions: Outcome after a Follow-Up of Minimum 2 Years.

Authors:  Manuel Waltenspül; Cyrill Suter; Jakob Ackermann; Nathalie Kühne; Sandro F Fucentese
Journal:  Cartilage       Date:  2021-06-11       Impact factor: 4.634

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.